Lineage Cell Therapeutics Hits New 52-Week High of $1.95

Lineage Cell Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 1.95 on October 31, 2025. This achievement highlights the company's notable performance within the Pharmaceuticals & Biotechnology sector, particularly impressive given its microcap status with a market capitalization of USD 283 million.
Over the past year, Lineage Cell Therapeutics has demonstrated a remarkable performance, boasting a 144.59% increase, significantly outpacing the S&P 500's growth of 19.89%. Despite being a loss-making entity, the company continues to attract attention due to its innovative approaches in the biotechnology field.

Key financial metrics reveal a price-to-book ratio of 5.85, indicating the market's valuation of the company's assets. Additionally, the company's debt-to-equity ratio stands at -0.85, reflecting a unique financial structure. However, it is important to note that the company does not offer dividends, and its return on equity is currently at -36.40%. The stock's previous 52-week low was recorded at USD 0.37, marking a significant turnaround in its market performance.